Compare XNET & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNET | INMB |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.3M | 64.7M |
| IPO Year | 2011 | 2018 |
| Metric | XNET | INMB |
|---|---|---|
| Price | $3.48 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 263.4K | ★ 309.0K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.29 | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $3.10 | $1.06 |
| 52 Week High | $8.80 | $2.60 |
| Indicator | XNET | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 25.02 |
| Support Level | N/A | N/A |
| Resistance Level | $6.10 | $1.52 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 46.02 | 6.78 |
Xunlei Ltd is a technology company providing distributed cloud services in China. It operates a powerful internet platform in China based on cloud technology to enable its users to quickly access, store, manage and consume digital media content on the internet. The company has expanded its products and services from PC-based devices to mobile devices in part through pre-installed acceleration products in mobile phones to further enlarge its user base and offer its users a wider range of access points. It provides a wide range of products and services across cloud acceleration and digital entertainment to deliver an efficient, smart and safe internet environment to its users.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.